Beyond Air’s oncology subsidiary, Beyond Cancer, reported that six of ten heavily pre‑treated patients remain alive 22‑40 months after a single intratumoral injection of its ultra‑high‑concentration nitric‑oxide (UNO) therapy. The data, presented at the AACR 2026 meeting in San Diego, show a median overall survival that has not yet been reached and highlight that two triple‑negative breast‑cancer patients are disease‑free.
The trial enrolled patients with breast, squamous‑cell, and melanoma tumors and was conducted without a control arm, underscoring that the results are preliminary and must be interpreted with caution. The small sample size limits definitive conclusions about efficacy, but the sustained survival of six patients after a single treatment is a notable milestone for a salvage‑stage population.
In addition to the clinical data, the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent titled “System and Method for Delivery of Gas to a Tissue.” The allowance strengthens the intellectual‑property foundation for the UNO platform and may support future regulatory and commercial development.
Beyond Air is a small‑cap company with a market capitalization of approximately $5.66 million and a GF Score of 38/100, indicating limited financial strength and profitability. The company reported $2.0 million in quarterly revenue in Q3 2026, a milestone driven by its core LungFit® platform, while continuing to incur net losses and burn cash. The oncology pipeline, including the UNO therapy, is therefore a critical growth lever for the company’s long‑term viability.
CEO Steve Lisi has emphasized the momentum in the company’s core respiratory business, noting that the LungFit PH system is approaching FDA clearance and that the company is scaling its commercial operations. While he has not commented directly on the UNO trial, his remarks underscore the importance of diversifying Beyond Air’s product portfolio beyond its respiratory focus.
The patent allowance was a positive catalyst for the company, and the trial data add to the pipeline’s promise. Investors remain mindful of the company’s financial fragility, but the combination of early clinical signals and strengthened IP may influence future valuation and partnership opportunities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.